In comparison, Kim et al. analyzed tumor-infiltrating lymphocytes in 33 primary lung lesions from advanced NSCLC and found that a Treg/CD8 ratio cutoff of 0.25 achieved a sensitivity and specificity of 82.6% and 65.4% in predicting response to anti-PD-1 treatment36. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.